Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes

被引:20
作者
Senda, C
Yamaura, Y
Kobayashi, K
Fujii, H
Minami, H
Sasaki, Y
Igarashi, T
Chiba, K
机构
[1] Chiba Univ, Fac Pharmaceut Sci, Biochem Pharmacol & Biotoxicol Lab, Inage Ku, Chiba 2638522, Japan
[2] Natl Canc Ctr Hosp E, Chiba, Japan
[3] Nippon Boehringer Ingelheim Co, Kawanishi Pharma Res Inst, Dept Drug Metab & Pharmacokinet, Kawanishi, Hyogo, Japan
关键词
CYP2D6*10; human liver microsomes; mexiletine;
D O I
10.1046/j.0306-5251.2001.01411.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To study the influence of CYP2D6*10 on the formation of p-hydroxymexiletine (PHM) and hydroxymethylmexiletine (HMM) using microsomes from human liver of known genotypes. Methods Microsomes from human livers of genotype CYP2D6*1/*1 (n = 5), *1/*10 (n = 6) and *10/*10 (n = 6) were used in this study. The formation of PHM and HMM was determined by high-performance liquid chromatography. Results The formation rates of PHM and HMM were decreased by more than 50% and 85% in CYP2D6*1/*10 and *10/*10 microsomes, respectively, compared with *1/*1 microsomes. Concl(u)sions The metabolism of mexiletine to form PHM and HMM appears to be impaired to a significant extent in human liver microsomes from hetero- and homozygotes of CYP2D6*10.
引用
收藏
页码:100 / 103
页数:4
相关论文
共 10 条
[1]   THE METABOLISM OF MEXILETINE IN RELATION TO THE DEBRISOQUINE SPARTEINE-TYPE POLYMORPHISM OF DRUG OXIDATION [J].
BROLY, F ;
VANDAMME, N ;
LIBERSA, C ;
LHERMITTE, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (04) :459-466
[2]  
CAMPBELL NPS, 1978, BRIT J CLIN PHARMACO, V6, P103, DOI 10.1111/j.1365-2125.1978.tb00833.x
[3]  
CHIBA K, 1993, DRUG METAB DISPOS, V21, P747
[4]  
CHIBA K, 1993, J PHARMACOL EXP THER, V266, P52
[5]   Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers [J].
Fukuda, T ;
Yamamoto, I ;
Nishida, Y ;
Zhou, Q ;
Ohno, M ;
Takada, K ;
Azuma, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) :450-453
[6]  
JOHANSSON I, 1994, MOL PHARMACOL, V46, P452
[7]   Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes [J].
Kubota, T ;
Yamaura, Y ;
Ohkawa, N ;
Hara, H ;
Chiba, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (01) :31-34
[8]   PROPRANOLOL DISPOSITION IN CHINESE SUBJECTS OF DIFFERENT CYP2D6 GENOTYPES [J].
LAI, ML ;
WANG, SL ;
LAI, MD ;
LIN, ET ;
TSE, M ;
HUANG, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (03) :264-268
[9]   Involvement of CYPIA2 in mexiletine metabolism [J].
Nakajima, M ;
Kobayashi, K ;
Shimada, N ;
Tokudome, S ;
Yamamoto, T ;
Kuroiwa, Y .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) :55-62
[10]  
TURGEON J, 1991, J PHARMACOL EXP THER, V259, P789